Retrospective analysis of real-world elacestrant use in two large Austrian cancer centers

Background

Elacestrant is an oral selective estrogen receptor degrader (SERD) approved for the treatment of hormone receptor–positive (HR-positive), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) following progression on endocrine therapy and CDK4/6 inhibitors. While randomized trial data from the EMERALD study demonstrated its clinical benefit, real-world evidence remains limited.